Cardioprotective effects of novel antioxidants post-myocardial infarction: An integrative review of preclinical and clinical data
1 AI-Zahrawi International University of Health Sciences. Allal Al Fassi Avenue, Medina Al Iran, Riad District.
Morocco, Rabat 10000,
2 Department of Medicine, La Faculté de Médecine et de Pharmacie de Marrakech, Université Cadi Ayyad Morocco, Marrakech 40000, Sidi Abbad, B.P. 7010 5.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 20(01), 253–269.
Article DOI: 10.30574/wjbphs.2024.20.1.0751
Publication history:
Received on 29 August 2024; revised on 05 October 2024; accepted on 08 October 2024
Abstract:
Myocardial infarction (MI), is still a major public health problem, and oxidative stress contributes to the degree of myocardial damage after MI. Oxygen-derived free radicals (ODFR) worsen myocardial injury and result in chronic heart failure in many patients. These harms have led to interest in antioxidant treatment to reduce these adverse effects; new antioxidants with the potential for cardioprotection are the subject of significant interest. This review summarizes basic and clinical research comparing the effectiveness of newly synthesized antioxidants in attenuating oxidative stress and enhancing recovery after myocardial infarction.
The review synthesizes evidence of a reduction in infarct size, enhancement of cardiac function, and repression of apoptosis in myocardial cells by the use of antioxidants from animal models. Melatonin, N-acetylcysteine, edaravone, and coenzyme Q10 demonstrated a wide range of preclinical positive effects by acting as ROS free radicals scavengers, modulating mitochondria dysfunction, and reducing inflammation. These findings are extrapolated from humans, although advances in antioxidant therapy are beginning to be viewed in initial clinical trials.
From human data, although clinical trials are scarce, the evidence of new antioxidants can improve point and long-term outcomes in patients undergoing MI, help to increase the contractility of the injured myocardium, and decrease the mortality level. However, some issues are still there, such as high inter- and intra-individual variability in patient response and dosing schedule, as well as adverse effects such as pro-oxidant activity at high Oral administered doses of melatonin. The limitations of the current research discussed in this review include the general lack of large-scale, well-controlled clinical trials and the need for long-term follow-up studies. This review also proposed future research directions for improving antioxidant applications in post-MI management.
Keywords:
Myocardial Infarction; Antioxidants; Cardioprotection; Oxidative Stress; Preclinical Studies; Clinical Trials; ROS.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0